All In Biotech

Drug Trial Radar · NCT00003678

Tamoxifen in Treating Women With Breast Cancer

A Large, Uniquely Simple, Randomised Study to Assess Much More Reliably the Balance of Benefits and Risks of Prolonging Adjuvant Tamoxifen Treatment in Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 20,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

20,000

Planned (sponsor's estimate)

Start

May 1991

Primary completion

Not stated

Sponsor

Lead sponsor
University Hospital BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of at least 2 years of tamoxifen with that of 5 additional years of tamoxifen in treating women who have breast cancer that has been surgically removed.

Conditions

  • Breast Cancer

Interventions

  • tamoxifen citrateDrug

  • adjuvant therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Research UK Clinical Trials Unit - Birmingham

    Birmingham, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.